Canada markets closed

Graybug Vision, Inc. (GRAY)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
0.6536-0.0513 (-7.28%)
At close: 04:00PM EST
0.6540 +0.00 (+0.06%)
After hours: 06:18PM EST
Full screen
Trade prices are not sourced from all markets
Previous Close0.7049
Open0.6898
Bid0.6610 x 2200
Ask0.6659 x 1400
Day's Range0.6536 - 0.6900
52 Week Range0.4500 - 1.5800
Volume13,853
Avg. Volume45,586
Market Cap14.093M
Beta (5Y Monthly)0.91
PE Ratio (TTM)N/A
EPS (TTM)-1.6220
Earnings DateMar 08, 2023 - Mar 13, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.50
  • GlobeNewswire

    Graybug and CalciMedica Enter into Definitive Merger Agreement

    – Merger to create Nasdaq-listed, clinical-stage biopharmaceutical company focused on advancing CalciMedica’s pipeline of first-in-class product candidates for life-threatening inflammatory diseases – Combined company is expected to be funded with cash and cash equivalents of approximately $35 million at closing, with an expected runway into the second half of 2024 – Phase 2b results in acute pancreatitis for lead product candidate Auxora expected in second half of 2023 – Companies will host joi

  • GlobeNewswire

    Graybug Vision Reports Financial Results for the Three and Nine Months Ended September 30, 2022

    REDWOOD CITY, Calif., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY) (“Graybug” or the “Company”), a clinical-stage biopharmaceutical company focused historically on developing transformative medicines for ocular diseases, today reported financial results for the three and nine months ended September 30, 2022. Financial Results for the Three Months Ended September 30, 2022 Net loss for the quarter ended September 30, 2022 was $9.8 million compared to $8.0 million for the s

  • GlobeNewswire

    Graybug Vision Reports Financial Results for the Three and Six Months Ended June 30, 2022, and Recent Corporate Developments

    BALTIMORE, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for ocular diseases, today provided an update on recent corporate developments and anticipated milestones, and reported financial results for the three and six months ended June 30, 2022. Recent Corporate Developments Announced review of strategic alternatives — On June 28, 2022, Graybug announced that its Board of Directors w